OA10535A - Complexes organométalliques du fer antipaludiques - Google Patents

Complexes organométalliques du fer antipaludiques Download PDF

Info

Publication number: OA10535A
Authority: OA; OAPI
Prior art keywords: alkyl; ferrocene; hydrogen; group; complex according
Prior art date: 1995-05-10

Application number

OA70125A

Other languages

English (en)

French (fr)

Inventor

Jacques Brocard

Jacques Lebibi

Lucien Maciejewski

Original Assignee

Univ Lille Sciences Tech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-10

Filing date

1997-11-10

Publication date

2002-04-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9478836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10535(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-10 Application filed by Univ Lille Sciences Tech filed Critical Univ Lille Sciences Tech

2002-04-26 Publication of OA10535A publication Critical patent/OA10535A/fr

Links

230000000078 anti-malarial effect Effects 0.000 title claims abstract description 16
125000002524 organometallic group Chemical group 0.000 title claims description 14
239000003430 antimalarial agent Substances 0.000 title description 10
150000002505 iron Chemical class 0.000 title 1
KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical group [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims abstract description 29
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 26
-1 Organometallic iron complexes Chemical class 0.000 claims abstract description 6
150000001875 compounds Chemical class 0.000 claims description 30
125000000217 alkyl group Chemical group 0.000 claims description 20
229910052739 hydrogen Inorganic materials 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
229940095064 tartrate Drugs 0.000 claims description 9
125000002252 acyl group Chemical group 0.000 claims description 8
125000005041 acyloxyalkyl group Chemical group 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical group 0.000 claims description 8
201000004792 malaria Diseases 0.000 claims description 7
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
150000001412 amines Chemical group 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
125000003277 amino group Chemical group 0.000 claims description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 claims 1
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract description 10
235000001258 Cinchona calisaya Nutrition 0.000 abstract description 6
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract description 5
229960000948 quinine Drugs 0.000 abstract description 5
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 15
229960003677 chloroquine Drugs 0.000 description 15
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 13
230000000694 effects Effects 0.000 description 10
229910052742 iron Inorganic materials 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
150000001299 aldehydes Chemical class 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
244000045947 parasite Species 0.000 description 6
125000001424 substituent group Chemical group 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
241000157855 Cinchona Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
238000006683 Mannich reaction Methods 0.000 description 4
241000224016 Plasmodium Species 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
238000009833 condensation Methods 0.000 description 4
230000005494 condensation Effects 0.000 description 4
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
241000223830 Plasmodium yoelii Species 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
150000002466 imines Chemical class 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000006138 lithiation reaction Methods 0.000 description 3
229960000901 mepacrine Drugs 0.000 description 3
238000000034 method Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
241000224017 Plasmodium berghei Species 0.000 description 2
241000223960 Plasmodium falciparum Species 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229940033495 antimalarials Drugs 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
125000004663 dialkyl amino group Chemical group 0.000 description 2
125000005265 dialkylamine group Chemical group 0.000 description 2
229940079593 drug Drugs 0.000 description 2
235000019256 formaldehyde Nutrition 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229960005179 primaquine Drugs 0.000 description 2
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000007704 transition Effects 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
KWVNKWCJDAWNAE-UHFFFAOYSA-N 2,3-dichloroquinoline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=CC2=C1 KWVNKWCJDAWNAE-UHFFFAOYSA-N 0.000 description 1
GHCKERHPOQWERJ-UHFFFAOYSA-N 3-aminoacridine Chemical compound C1=CC=CC2=NC3=CC(N)=CC=C3C=C21 GHCKERHPOQWERJ-UHFFFAOYSA-N 0.000 description 1
PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical class C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
YGGTVPCTAKYCSQ-UHFFFAOYSA-N 6-methoxyquinolin-8-amine Chemical compound N1=CC=CC2=CC(OC)=CC(N)=C21 YGGTVPCTAKYCSQ-UHFFFAOYSA-N 0.000 description 1
WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
102100029095 Exportin-1 Human genes 0.000 description 1
102100029091 Exportin-2 Human genes 0.000 description 1
101710147878 Exportin-2 Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
206010022971 Iron Deficiencies Diseases 0.000 description 1
208000009182 Parasitemia Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
240000003705 Senecio vulgaris Species 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
150000001337 aliphatic alkines Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001414 amino alcohols Chemical group 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
125000004427 diamine group Chemical group 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
108700002148 exportin 1 Proteins 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000013110 organic ligand Substances 0.000 description 1
238000006146 oximation reaction Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
125000003410 quininyl group Chemical group 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
VFJKXAYBWDJZAE-UHFFFAOYSA-N sodium;cyclopenta-1,3-diene;2-(cyclopenta-2,4-diene-1-carbonyl)benzoic acid;iron(2+) Chemical compound [Na+].[Fe+2].C1C=CC=C1.OC(=O)C1=CC=CC=C1C(=O)[C-]1C=CC=C1 VFJKXAYBWDJZAE-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
210000003812 trophozoite Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F17/00—Metallocenes
- C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

OA70125A 1995-05-10 1997-11-10 Complexes organométalliques du fer antipaludiques OA10535A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9505532A FR2733985B1 (fr)	1995-05-10	1995-05-10	Complexes organometalliques du fer antipaludiques

Publications (1)

Publication Number	Publication Date
OA10535A true OA10535A (fr)	2002-04-26

Family

ID=9478836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA70125A OA10535A (fr)	1995-05-10	1997-11-10	Complexes organométalliques du fer antipaludiques

Country Status (14)

Country	Link
US (1)	US6127543A (de)
EP (1)	EP0824536B1 (de)
JP (1)	JP4394163B2 (de)
AP (1)	AP953A (de)
AT (1)	ATE204581T1 (de)
AU (1)	AU718946B2 (de)
BR (1)	BR9608473A (de)
DE (1)	DE69614679T2 (de)
DK (1)	DK0824536T3 (de)
ES (1)	ES2163022T3 (de)
FR (1)	FR2733985B1 (de)
OA (1)	OA10535A (de)
PT (1)	PT824536E (de)
WO (1)	WO1996035698A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0205455D0 (en)	2002-03-07	2002-04-24	Molecular Sensing Plc	Nucleic acid probes, their synthesis and use
FR2952823B1 (fr)	2009-10-30	2012-04-20	Sanofi Aventis	Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
FR2951945B1 (fr)	2009-11-05	2013-08-09	Sanofi Aventis	Composition pharmaceutique
FR2961209B1 (fr) *	2010-06-11	2013-03-01	Sanofi Aventis	Procede de synthese de la ferroquine par amination reductrice convergente.
WO2012104204A1 (en)	2011-01-31	2012-08-09	Vifor (International) Ag	Iron-carbohydrate complex compounds for the intravenous therapy of malaria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1470210A (en) *	1974-10-30	1977-04-14	Edwards E	Organometallic derivatives of penicillin
DE2815930A1 (de) *	1978-04-13	1979-10-18	Bayer Ag	Duengemittel zur versorgung von pflanzen mit eisen
EP0214933A3 (de) *	1985-09-03	1989-05-24	Ciba-Geigy Ag	Kombinationspräparate zur Behandlung von Malaria

1995
- 1995-05-10 FR FR9505532A patent/FR2733985B1/fr not_active Expired - Lifetime
1996
- 1996-05-10 AP APAP/P/1997/001141A patent/AP953A/en active
- 1996-05-10 AT AT96916196T patent/ATE204581T1/de active
- 1996-05-10 BR BR9608473-1A patent/BR9608473A/pt not_active IP Right Cessation
- 1996-05-10 DK DK96916196T patent/DK0824536T3/da active
- 1996-05-10 JP JP53384296A patent/JP4394163B2/ja not_active Expired - Lifetime
- 1996-05-10 WO PCT/FR1996/000721 patent/WO1996035698A1/fr not_active Ceased
- 1996-05-10 US US08/952,093 patent/US6127543A/en not_active Expired - Lifetime
- 1996-05-10 ES ES96916196T patent/ES2163022T3/es not_active Expired - Lifetime
- 1996-05-10 EP EP96916196A patent/EP0824536B1/de not_active Expired - Lifetime
- 1996-05-10 DE DE69614679T patent/DE69614679T2/de not_active Expired - Lifetime
- 1996-05-10 AU AU59037/96A patent/AU718946B2/en not_active Expired
- 1996-05-10 PT PT96916196T patent/PT824536E/pt unknown
1997
- 1997-11-10 OA OA70125A patent/OA10535A/fr unknown

Also Published As

Publication number	Publication date
DE69614679D1 (de)	2001-09-27
JPH11511738A (ja)	1999-10-12
ES2163022T3 (es)	2002-01-16
AP9701141A0 (en)	1998-01-31
DE69614679T2 (de)	2002-06-27
BR9608473A (pt)	1999-11-30
FR2733985A1 (fr)	1996-11-15
AU718946B2 (en)	2000-05-04
EP0824536B1 (de)	2001-08-22
ATE204581T1 (de)	2001-09-15
WO1996035698A1 (fr)	1996-11-14
AP953A (en)	2001-04-02
US6127543A (en)	2000-10-03
EP0824536A1 (de)	1998-02-25
AU5903796A (en)	1996-11-29
DK0824536T3 (da)	2001-12-17
JP4394163B2 (ja)	2010-01-06
PT824536E (pt)	2002-02-28
FR2733985B1 (fr)	1997-07-18

Publication	Publication Date	Title
Benoit-Vical et al.	2007	Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes
Navarro et al.	2012	Bioorganometallic compounds with antimalarial targets: inhibiting hemozoin formation
Salas et al.	2013	Metalloantimalarials
Lenz et al.	2021	Taking different roads: l‐Tryptophan as the origin of psilocybe natural products
Minori et al.	2020	Comparing the Antileishmanial Activity of Gold (I) and Gold (III) Compounds in L. amazonensis and L. braziliensis in Vitro
Shreekant et al.	2016	4-Aminoquinolines: an overview of antimalarial chemotherapy
WO2001096322A1 (fr)	2001-12-20	Derives de diamino phenothiazine et composition comportant des derives de diamino phenothiazine
EP0824536B1 (de)	2001-08-22	Organo-eisenkomlexe mit wirkung gegen malaria
RU2222532C2 (ru)	2004-01-27	Соединения ряда бензофуроксана, способ их получения (варианты), фармацевтическая композиция, способ получения парентерального состава и способ лечения коронарных сердечных заболеваний
EP2542235A1 (de)	2013-01-09	Verwendung von riluzol zur behandlung oder vermeidung der nebenwirkungen von antineoplastika
Golding et al.	2025	Ferrocenyl quinoline-benzimidazole hybrids: a multistage strategy to combat drug-resistant malaria
WO2006111647A1 (fr)	2006-10-26	Association entre la ferroquine et un derive d’artemisinine pour le traitement du paludisme
Ridley et al.	1998	Quinoline antimalarials
WO2011001109A1 (fr)	2011-01-06	Methodes et compositions pour le traitement de cancers
US20130324598A1 (en)	2013-12-05	Treating mycobacterial infection with cu+/++ boosting therapeutics
WO2013117870A1 (fr)	2013-08-15	Méthodes et compositions pour le traitement de cancer
FR2542614A1 (fr)	1984-09-21	Compositions pharmaceutiques a activite anti-neoplastique, comprenant un compose de selenium et un acide carboxylique, un aldehyde ou une cetone
EP0785924B1 (de)	2000-05-03	Bis-2-aminopyridine, verfahren zu ihrer herstelung und ihre verwendung zur bekämpfung von parasitosen
Boldron et al.	2005	Preparation of Cyclo‐Phen‐Type Ligands: Chelators of Metal Ions as Potential Therapeutic Agents in the Treatment of Neurodegenerative Diseases
Ukrainets et al.	2014	4-Hydroxyquinolin-2-ones and their Close Structural Analogues as a New Source of Highly Effective Pain
EP1469845A2 (de)	2004-10-27	Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen
FR2722987A1 (fr)	1996-02-02	Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux
OA13294A (fr)	2007-04-13	Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques.
US7265248B1 (en)	2007-09-04	Compositions and methods for the treatment of malaria
WO2003059352B1 (fr)	2004-04-15	Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires